CLDI
Calidi·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 0
Bearish signal 2
Low Cash Short-term Debt Ratio
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CLDI
Calidi Biotherapeutics, Inc.
A clinical-stage immuno-oncology company
Biological Technology
Invalid Date
11/17/2022
American Stock Exchange
28
12-31
Common stock
4475 Executive Drive, Suite 200, San Diego, California 92121
--
Calidi Biotherapeutics, Inc., founded as a clinical-stage immuno-oncology company in Delaware, is developing a proprietary platform based on allogeneic stem cells to enhance and deliver oncolytic viruses and possibly molecules to cancer patients. The company is currently developing two proprietary stem cell-based platforms and an enveloped vaccinia virus platform designed to protect oncolytic viruses, both natural and engineered, from being neutralized by the patient's immune defenses, allowing tumor cells to be infected more and resulting in potential improvements in the anti-tumor activity of oncolytic viruses over traditional "naked" oncolytic virus therapies.
Company Financials
EPS
CLDI has released its 2025 Q3 earnings. EPS was reported at -2.21, versus the expected -1.68, missing expectations. The chart below visualizes how CLDI has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
